Previous close | 5.30 |
Open | 5.30 |
Bid | 4.10 |
Ask | 6.00 |
Strike | 20.00 |
Expiry date | 2024-08-16 |
Day's range | 5.30 - 5.30 |
Contract range | N/A |
Volume | |
Open interest | 8 |
Alkermes plc (Nasdaq: ALKS) today announced new data from the full narcolepsy type 1 (NT1) cohort of a phase 1b, proof-of-concept study evaluating ALKS 2680, the company's novel, investigational, oral orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy. The data are being presented at SLEEP 2024, the 38th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 1-5, 2024 in Houston.
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The top five biotech stocks today have several commonalities. Among them are strong ratings. Some show promising charts and are Tech Leaders.